120 related articles for article (PubMed ID: 30320363)
21. Preclinical Evaluation of [
Oroujeni M; Garousi J; Andersson KG; Löfblom J; Mitran B; Orlova A; Tolmachev V
Cells; 2018 Sep; 7(9):. PubMed ID: 30231504
[TBL] [Abstract][Full Text] [Related]
22. Preparation and Evaluation of (99m)Tc-Epidermal Growth Factor Receptor (EGFR)-Peptide Nucleic Acid for Visualization of EGFR Messenger RNA Expression in Malignant Tumors.
Zhao X; Wang N; Ren X; Zhang J; Wang J; Han J; Jia L; Liu Y; Zhang Z
J Nucl Med; 2014 Jun; 55(6):1008-16. PubMed ID: 24744447
[TBL] [Abstract][Full Text] [Related]
23. Disparity between in vivo EGFR expression and 89Zr-labeled cetuximab uptake assessed with PET.
Aerts HJ; Dubois L; Perk L; Vermaelen P; van Dongen GA; Wouters BG; Lambin P
J Nucl Med; 2009 Jan; 50(1):123-31. PubMed ID: 19091906
[TBL] [Abstract][Full Text] [Related]
24. Preparation and evaluation of (68)Ga-DOTA-hEGF for visualization of EGFR expression in malignant tumors.
Velikyan I; Sundberg AL; Lindhe O; Höglund AU; Eriksson O; Werner E; Carlsson J; Bergström M; Långström B; Tolmachev V
J Nucl Med; 2005 Nov; 46(11):1881-8. PubMed ID: 16269603
[TBL] [Abstract][Full Text] [Related]
25. Improved contrast of affibody-mediated imaging of HER3 expression in mouse xenograft model through co-injection of a trivalent affibody for in vivo blocking of hepatic uptake.
Rosestedt M; Andersson KG; Rinne SS; Leitao CD; Mitran B; Vorobyeva A; Ståhl S; Löfblom J; Tolmachev V; Orlova A
Sci Rep; 2019 May; 9(1):6779. PubMed ID: 31043683
[TBL] [Abstract][Full Text] [Related]
26. Molecular design and optimization of 99mTc-labeled recombinant affibody molecules improves their biodistribution and imaging properties.
Wållberg H; Orlova A; Altai M; Hosseinimehr SJ; Widström C; Malmberg J; Ståhl S; Tolmachev V
J Nucl Med; 2011 Mar; 52(3):461-9. PubMed ID: 21321280
[TBL] [Abstract][Full Text] [Related]
27. Comparison of tumor‑targeting properties of directly and indirectly radioiodinated designed ankyrin repeat protein (DARPin) G3 variants for molecular imaging of HER2.
Vorobyeva A; Sсhulga A; Konovalova E; Güler R; Mitran B; Garousi J; Rinne S; Löfblom J; Orlova A; Deyev S; Tolmachev V
Int J Oncol; 2019 Apr; 54(4):1209-1220. PubMed ID: 30968147
[TBL] [Abstract][Full Text] [Related]
28. Comparative biodistribution of imaging agents for in vivo molecular profiling of disseminated prostate cancer in mice bearing prostate cancer xenografts: focus on 111In- and 125I-labeled anti-HER2 humanized monoclonal trastuzumab and ABY-025 affibody.
Malmberg J; Sandström M; Wester K; Tolmachev V; Orlova A
Nucl Med Biol; 2011 Nov; 38(8):1093-102. PubMed ID: 22137850
[TBL] [Abstract][Full Text] [Related]
29. Assessment of epidermal growth factor receptor with 99mTc-ethylenedicysteine-C225 monoclonal antibody.
Schechter NR; Yang DJ; Azhdarinia A; Kohanim S; Wendt R; Oh CS; Hu M; Yu DF; Bryant J; Ang KK; Forster KM; Kim EE; Podoloff DA
Anticancer Drugs; 2003 Jan; 14(1):49-56. PubMed ID: 12544258
[TBL] [Abstract][Full Text] [Related]
30. Increasing the Net Negative Charge by Replacement of DOTA Chelator with DOTAGA Improves the Biodistribution of Radiolabeled Second-Generation Synthetic Affibody Molecules.
Westerlund K; Honarvar H; Norrström E; Strand J; Mitran B; Orlova A; Eriksson Karlström A; Tolmachev V
Mol Pharm; 2016 May; 13(5):1668-78. PubMed ID: 27010700
[TBL] [Abstract][Full Text] [Related]
31. Imaging of human epidermal growth factor receptor type 2 expression with 18F-labeled affibody molecule ZHER2:2395 in a mouse model for ovarian cancer.
Heskamp S; Laverman P; Rosik D; Boschetti F; van der Graaf WT; Oyen WJ; van Laarhoven HW; Tolmachev V; Boerman OC
J Nucl Med; 2012 Jan; 53(1):146-53. PubMed ID: 22173842
[TBL] [Abstract][Full Text] [Related]
32. Tumor targeting using anti-epidermal growth factor receptor (ior egf/r3) immunoconjugate with a tetraaza macrocyclic agent (DO3A-EA).
Mishra G; Panwar P; Mishra AK
Mol Imaging; 2012; 11(5):408-16. PubMed ID: 22954185
[TBL] [Abstract][Full Text] [Related]
33. 99mTc-Hydrazinonicotinamide epidermal growth factor-polyethylene glycol-quantum dot imaging allows quantification of breast cancer epidermal growth factor receptor expression and monitors receptor downregulation in response to cetuximab therapy.
Jung KH; Choe YS; Paik JY; Lee KH
J Nucl Med; 2011 Sep; 52(9):1457-64. PubMed ID: 21849406
[TBL] [Abstract][Full Text] [Related]
34. In vivo and in vitro uptake of 111In, delivered with the affibody molecule (ZEGFR:955)2, in EGFR expressing tumour cells.
Nordberg E; Orlova A; Friedman M; Tolmachev V; Ståhl S; Nilsson FY; Glimelius B; Carlsson J
Oncol Rep; 2008 Apr; 19(4):853-7. PubMed ID: 18357367
[TBL] [Abstract][Full Text] [Related]
35. On the selection of a tracer for PET imaging of HER2-expressing tumors: direct comparison of a 124I-labeled affibody molecule and trastuzumab in a murine xenograft model.
Orlova A; Wållberg H; Stone-Elander S; Tolmachev V
J Nucl Med; 2009 Mar; 50(3):417-25. PubMed ID: 19223403
[TBL] [Abstract][Full Text] [Related]
36. Radionuclide therapy using ¹³¹I-labeled anti-epidermal growth factor receptor-targeted nanoparticles suppresses cancer cell growth caused by EGFR overexpression.
Li W; Liu Z; Li C; Li N; Fang L; Chang J; Tan J
J Cancer Res Clin Oncol; 2016 Mar; 142(3):619-32. PubMed ID: 26573511
[TBL] [Abstract][Full Text] [Related]
37. SPECT imaging evaluation of
Shih BB; Chang YF; Cheng CC; Yang HJ; Chang KW; Ho AS; Lin HC; Yeh C; Chang CC
J Chin Med Assoc; 2017 Dec; 80(12):766-773. PubMed ID: 28969991
[TBL] [Abstract][Full Text] [Related]
38. Gallium-68-labeled affibody molecule for PET imaging of PDGFRβ expression in vivo.
Strand J; Varasteh Z; Eriksson O; Abrahmsen L; Orlova A; Tolmachev V
Mol Pharm; 2014 Nov; 11(11):3957-64. PubMed ID: 24972112
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of the first
Honarvar H; Müller C; Cohrs S; Haller S; Westerlund K; Karlström AE; van der Meulen NP; Schibli R; Tolmachev V
Nucl Med Biol; 2017 Feb; 45():15-21. PubMed ID: 27837664
[TBL] [Abstract][Full Text] [Related]
40. 99mTc-labeled small-molecule inhibitors of prostate-specific membrane antigen for molecular imaging of prostate cancer.
Hillier SM; Maresca KP; Lu G; Merkin RD; Marquis JC; Zimmerman CN; Eckelman WC; Joyal JL; Babich JW
J Nucl Med; 2013 Aug; 54(8):1369-76. PubMed ID: 23733925
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
